Furthermore, owing to the rapid and specific accumulation of ZHER2:2395-IR700 in HER2-positive tumours, the conjugate could be used in the clinic as a tool for both NIR fluorescence image-guided tumour resection and simultaneous light irradiation-mediated elimination of residual cancer cells as a trigger to activate the host anti-tumour immune responses. This evidence concerns the gene ERBB2 and neoplasm.